Paul S. Aisen
Works at
University of Southern California
Professor
Sources: reporter.nih.gov
Grants and prizes
R01, Randomized Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease over 18 Months, R01AG065248, 2020–2027, 25 Aug 2026
U24, Alzheimer's Clinical Trials Consortium (ACTC), U24AG057437, 2017–2028, 19 Aug 2026
R01, The Ante-Amyloid Treatment of Alzheimer's disease (A3) Trial and Alzheimer Plasma EXtension (APEX) Study, R01AG095009, 2025–2030, 19 Aug 2026
R01, Life’s end Benefits of CannaBidiol and TetrahYdrocannabinol (LiBBY) Open-Label Extension (OLE) Study, R01AG095004, 2025–2028, 19 Aug 2026
R01, API A4 Alzheimer's Prevention Trial, R01AG058468, 2018–2025, 11 Mar 2025
R01, Combination anti-amyloid therapy for preclinical Alzheimer's disease, R01AG061848, 2018–2025, 10 Jul 2024
R01, Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study, R01AG063689, 2019–2025, 29 Dec 2023
R01, The A3 Study: Ante-Amyloid Prevention of Alzheimer's disease, R01AG054029, 2016–2024, 16 Jun 2023
Sources: reporter.nih.gov